Clinical Trial Update: Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase II trial update for Cadonilimab plus Capecitabine as adjuvant therapy for combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Hepatocellular-cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Cadonilimab
• Capecitabine (capecitabine)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Combined Hepatocellular-cholangiocarcinoma, Liver Neoplasms | Phase 2 | Status: NOT_YET_RECRUITING